ProCE Banner Activity

PARP Combinations in Prostate Cancer: PARPi Plus Androgen Receptor Inhibitors

Slideset Download
Download these slides from a live Webinar to gain expert insight on the rationale for combining PARP inhibitors and AR-directed therapy in mCRPC including the latest evidence from ASCO GU 2021.

Released: February 19, 2021

Expiration: February 18, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer TEXT Only

Faculty Disclosure

Primary Author

Neal D. Shore, MD, FACS

Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina